$132.22
0.00% day before yesterday
Nasdaq, Aug 30, 12:37 am CET
ISIN
US09062X1037
Symbol
BIIB

Biogen Target price 2025 - Analyst rating & recommendation

Biogen Classifications & Recommendation:

Buy
47%
Hold
51%
Sell
2%

Biogen Price Target

Target Price $155.04
Price $132.22
Potential 17.26%
Number of Estimates 32
32 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $155.04. This is 17.26% higher than the current stock price. The highest price target is $273.00 106.47% , the lowest is $119.18 9.86% .
A rating was issued by 43 analysts: 20 Analysts recommend Biogen to buy, 22 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 17.26% . Most analysts recommend the Biogen stock at Hold.

Sales and Margin forecast 2025, 2026 to 2032


Dec '24 2025
Estimates
Revenue Billion $ 9.68 9.87
1.62% 2.00%
EBITDA Margin 31.40% 34.08%
27.87% 8.55%
Net Margin 16.87% 24.05%
42.89% 42.57%

37 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.9b . This is 1.28% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $10.5b 5.34% , the lowest is $9.3b 6.73% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $9.7b 1.62%
2025 $9.9b 2.00%
2026 $9.5b 4.03%
2027 $9.5b 0.24%
2028 $9.7b 1.75%
2029 $9.7b 0.05%
2030 $9.6b 1.02%
2031 $9.4b 1.62%
2032 $9.4b 0.37%

17 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.4b . This is 5.28% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.0b 23.88% , the lowest is $3.0b 7.18% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $3.0b 25.80%
2025 $3.4b 10.70%
2026 $3.5b 3.18%
2027 $3.5b 0.84%
2028 $3.9b 11.69%
2029 $4.0b 2.25%
2030 $4.0b 0.80%
2031 $5.6b 40.79%
2032 $6.1b 9.78%

EBITDA Margin

2024 31.40% 27.87%
2025 34.08% 8.55%
2026 36.64% 7.51%
2027 36.85% 0.57%
2028 40.46% 9.80%
2029 41.39% 2.30%
2030 41.48% 0.22%
2031 59.36% 43.11%
2032 64.93% 9.38%

38 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $2.4b . This is 55.07% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 62.75% , the lowest is $2.2b 45.59% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $1.6b 40.57%
2025 $2.4b 45.41%
2026 $2.4b 0.44%
2027 $2.5b 3.98%
2028 $2.6b 4.13%
2029 $2.6b 0.36%
2030 $2.5b 4.06%
2031 $2.5b 0.56%
2032 $2.5b 2.88%

Net Margin

2024 16.87% 42.89%
2025 24.05% 42.57%
2026 24.95% 3.74%
2027 25.88% 3.73%
2028 26.48% 2.32%
2029 26.59% 0.42%
2030 25.77% 3.08%
2031 26.35% 2.25%
2032 27.01% 2.50%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032


Dec '24 2025
Estimates
Earnings Per Share $ 11.19 16.19
40.40% 44.68%
P/E 8.17
EV/Sales 2.32

38 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $16.19 . This is 55.23% higher than earnings per share in the financial year 2024. The highest EPS forecast is $16.99 62.90% , the lowest is $15.20 45.73% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $11.19 40.40%
2025 $16.19 44.68%
2026 $16.12 0.43%
2027 $16.76 3.97%
2028 $17.45 4.12%
2029 $17.51 0.34%
2030 $16.80 4.05%
2031 $16.90 0.60%
2032 $17.38 2.84%

P/E ratio

Current 12.68 50.90%
2025 8.17 35.55%
2026 8.20 0.37%
2027 7.89 3.78%
2028 7.58 3.93%
2029 7.55 0.40%
2030 7.87 4.24%
2031 7.83 0.51%
2032 7.61 2.81%

Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.32 and an P/S ratio of 1.96 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.29 35.31%
2025 2.32 1.37%
2026 2.42 4.20%
2027 2.41 0.24%
2028 2.37 1.72%
2029 2.37 0.05%
2030 2.40 1.02%
2031 2.44 1.65%
2032 2.43 0.37%

P/S ratio

Current 1.94 37.19%
2025 1.96 1.30%
2026 2.05 4.20%
2027 2.04 0.24%
2028 2.01 1.72%
2029 2.01 0.05%
2030 2.03 1.03%
2031 2.06 1.65%
2032 2.05 0.37%

Current Biogen Upgrades & Downgrades

Analyst Rating Action Date
Piper Sandler
Neutral
Neutral
Unchanged Aug 14 2025
HC Wainwright & Co.
Buy
Buy
Unchanged Aug 01 2025
RBC Capital
Outperform
Outperform
Unchanged Aug 01 2025
Morgan Stanley
Equal-Weight
Equal-Weight
Unchanged Aug 01 2025
Citigroup
Neutral
Neutral
Unchanged Aug 01 2025
RBC Capital
Outperform
Outperform
Unchanged Jun 27 2025
HC Wainwright & Co.
Buy
Buy
Unchanged Jun 26 2025
Analyst Rating Date
Unchanged
Piper Sandler:
Neutral
Neutral
Aug 14 2025
Unchanged
HC Wainwright & Co.:
Buy
Buy
Aug 01 2025
Unchanged
RBC Capital:
Outperform
Outperform
Aug 01 2025
Unchanged
Morgan Stanley:
Equal-Weight
Equal-Weight
Aug 01 2025
Unchanged
Citigroup:
Neutral
Neutral
Aug 01 2025
Unchanged
RBC Capital:
Outperform
Outperform
Jun 27 2025
Unchanged
HC Wainwright & Co.:
Buy
Buy
Jun 26 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today